title: Treatment with177Lu-DOTATATE: Past, present and future.
authors.affiliation: Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Grupo de Trabajo de Endocrinología de la SEMNIM. Electronic address: mestorch@santpau.cat.
authors.forename: M
authors.initials: M
authors.lastname: Estorch
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D005544:Forecasting; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D005770:Gastrointestinal Neoplasms / Q000532:radiotherapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007880:Legislation, Drug; D008187:Lutetium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000378:metabolism*; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011868:Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013030:Spain
chemical_list: D009363:Neoplasm Proteins; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D008187:Lutetium; C447941:lutetium Lu 177 dotatate; C000615061:Lutetium-177; C093733:somatostatin receptor 2; D015282:Octreotide